Abstract 137P
Background
Recent single-cell DNA sequencing (scDNA-seq) technologies have enabled the parallel investigation of thousands of individual cells. This is required for accurately reconstructing tumour evolution, during which cancer cells acquire a multitude of different genetic alterations. Although the evolutionary analysis of scDNA-seq datasets is complex due to their unique combination of errors and missing data, several methods have been developed to infer single-cell tumour phylogenies by integrating estimates of the false positive and false negative error rates. This integration relies on the assumption that errors are uniformly distributed both within and across cells. However, this assumption does not always hold; error rates depend on sequencing coverage, which is not constant within or across cells in a sequencing experiment due to, e.g., copy-number alterations and the replication status of a cell, limiting the accuracy of existing methods.
Methods
To address this challenge, we developed PHANTOM, a novel single-cell phylogenetic method that integrates raw sequencing read counts into a statistical framework to robustly correct the errors and missing data. PHANTOM includes bootstrapping to correct for high error frequency genomic positions and a fast probabilistic heuristic based on hypothesis testing to distinguish the remaining errors from truly observed genotypes.
Results
We demonstrate the improved accuracy and robustness of our method compared to existing approaches across several simulation settings. To demonstrate its impact, we applied our method to scDNA-seq datasets comprising >25,000 cells from 31 patients with triple-negative breast cancer or high-grade serous ovarian cancer, as well as targeted scDNA-seq from a cohort of 123 patients with acute myeloid leukaemia, revealing more accurate phylogenies consistent with copy-number alterations.
Conclusions
We developed PHANTOM, a novel single-cell phylogenetic method that accurately and robustly infers single-cell tumour phylogenies. We applied PHANTOM to scDNA-seq cancer datasets, revealing its potential to investigate tumour evolution at unprecedented resolution.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
120P - Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
Presenter: Nnenna Kanu
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Comprehensive multi-omics profiling identifies prognostic and predictive subtypes in renal cell carcinoma
Presenter: Sanha Park
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Copy number from ulcWGS to predict TNBC molecular subtypes in the IBCSG 22-00 trial
Presenter: Andrea Joaquin Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
124P - Targeting neoantigens in chronic lymphocytic leukemia (CLL) for personalized T cell therapy
Presenter: Gurvinder Kaur
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification
Presenter: Ivan Martinez de Estibariz Royuela
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Genomic and transcriptomic profiles define smokers and non-smokers lung squamous cell carcinoma patients
Presenter: Matteo Canale
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Metastatic migrations in lung cancer: Insights from the PEACE autopsy programme
Presenter: Sonya Hessey
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - NGS prescreening program for refractory solid tumors outside standard indications in a public network of cancer centers
Presenter: Paula Sàbat Viltró
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Transcriptomic analysis of patients with metastatic hormone-sensitive prostate cancer to identify genomic signatures involved in the transition from androgen-dependent to androgen-independent phenotype
Presenter: Giovanna Pecoraro
Session: Cocktail & Poster Display session
Resources:
Abstract